ASCO 2010: New Treatments for CML

News
Article

Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

Ariana Pelosci
July 10th 2025
Article

A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Jax DiEugenio
June 17th 2025
Article

Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.

Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Chris Ryan
June 17th 2025
Article

Ponatinib extended EFS and PFS in patients with newly diagnosed, Ph-positive acute lymphoblastic leukemia who did not achieve MRD negativity after induction.